Oncoinvent ASACHIX:ONCINO 36 Current Ratio is 3.23 as of Dec. 2025, which is 47% below its 10-year median of 6.12. GuruFocus rates CHIX:ONCINO with a GF Score™ of 36/100 and a GF Value™ of kr20,159.96. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Oncoinvent ASA ranks worse than 55.78% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Oncoinvent ASA's current ratio for the quarter that ended in Dec. 2025 was 3.23.
Oncoinvent ASA has a current ratio of 3.23. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Oncoinvent ASA's Current Ratio or its related term are showing as below:
CHIX:ONCINo'
s Current Ratio Range Over the Past 10 Years
Min: 2.14 Med: 6.12 Max: 11.29
Current: 3.23
During the past 11 years, Oncoinvent ASA's highest Current Ratio was 11.29. The lowest was 2.14. And the median was 6.12.
CHIX:ONCINo's Current Ratio is ranked worse than 55.78% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs CHIX:ONCINo: 3.23
Oncoinvent ASA (CHIX:ONCINo) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Oncoinvent ASA Current Ratio Related Terms
Oncoinvent ASA Current Ratio Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Current Ratio distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Current Ratio of 3.23 as of Dec. 2025. This is 47% below median its historical median of 6.12. Over the past decade, Oncoinvent ASA's Current Ratio has ranged from 2.14 to 11.29. According to the industry distribution chart, Oncoinvent ASA ranks #787 out of 1411 companies in the Biotechnology industry, placing it in the top 55.8%.
Is Oncoinvent ASA's Current Ratio too high?
Oncoinvent ASA's current Current Ratio of 3.23 is 47% below median its 10-year median of 6.12. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 11.29. The Biotechnology industry median Current Ratio is 3.91. Oncoinvent ASA's value of 3.23 is 17.4% below this industry median. Based on the distribution chart, Oncoinvent ASA ranks #787 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #787 out of 1411 companies for Current Ratio. This places Oncoinvent ASA in the lower half of its industry. The industry median Current Ratio is 3.91. Oncoinvent ASA's value of 3.23 is 17.4% below this benchmark. Historically, Oncoinvent ASA's own Current Ratio has ranged from 2.14 to 11.29 over the past decade. While the company's 10-year median is 6.12 vs. the industry median of 3.91, Oncoinvent ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncoinvent ASA's current Current Ratio of 3.23 is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current Current Ratio is 3.23, which is 47% below median its own 10-year median of 6.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Current Ratio of 3.23. The stock's GF Value™ is kr20,159.96, compared to a current price of kr1,039.91 — trading 94.8% below its estimated fair value. The current Current Ratio is 3.23, which is 47% below median its 10-year median of 6.12 and 17.4% below the Biotechnology industry median of 3.91. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Current Ratio is 3.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 94.8% below its estimated GF Value™ of kr20,159.96.
Key valuation signals for CHIX:ONCINO:
Current Ratio: 3.23 (47% below median its 10-year median of 6.12)
GF Value™: kr20,159.96 vs. price of kr1,039.91 (94.8% below fair value)
Industry Position: 17.4% below the Biotechnology median (#787 of 1411)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
